ロード中...
The KHENERGY Study: Safety and Efficacy of KH176 in Mitochondrial m.3243A>G Spectrum Disorders
KH176 is a potent intracellular reduction–oxidation‐modulating compound developed to treat mitochondrial disease. We studied tolerability, safety, pharmacokinetics, pharmacodynamics, and efficacy of twice daily oral 100 mg KH176 for 28 days in a double‐blind, randomized, placebo‐controlled, two‐way...
保存先:
| 出版年: | Clin Pharmacol Ther |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6704357/ https://ncbi.nlm.nih.gov/pubmed/30058726 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1197 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|